Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients with Relapsed or Resistant CD20 Positive B-NHL

NCT03664635 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT03664635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03664635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients with Relapsed or Resistant CD20 Positive B-NHL
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
September 25, 2018
Completion date
September 17, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent, b-cell lymphoma refractory, non-hodgkin's lymphoma, relapsed or refractory b-cell non-hodgkin's lymphoma